Efficacy and main therapeutic effects of Rucaparib

The core efficacy of Rucaparib comes from its unique mechanism of action as a PARP inhibitor. PARP is a type of enzyme closely related to DNA repair. When body cells are damaged by external factors or internal mechanisms that cause DNA single-strand breaks, PARP can help repair this damage. But for tumor cells, this repair ability actually gives them a "survival advantage." Rucapanib inhibits PARP activity and weakens the repair ability of cancer cells, leading to accumulation of DNA damage and ultimately cell death. This mechanism is particularly significant in patients carrying BRCA1/2 gene mutations, because the DNA repair pathways of these mutated patients are inherently defective, and the use of rucapanib can further enhance the attack on cancer cells.

In clinical application, rucapanib is widely used in the maintenance treatment and management of recurrent diseases such as ovarian cancer, fallopian tube cancer, primary peritoneal cancer and other malignant tumors. For those patients who still need treatment after platinum-based chemotherapy, rucapanib can significantly extend progression-free survival and improve quality of life. This effect makes it an important choice in maintenance treatment of tumors.

In addition to its application in female reproductive system tumors, rucapanib has also shown potential efficacy in other solid tumors carryingBRCA gene mutations, including prostate cancer and pancreatic cancer. Currently, several international studies are exploring its wider indications, which provides clinicians with more possibilities for personalized treatment.

Overall, the efficacy of rucapanib is not only to directly inhibit tumor growth, but more importantly, to provide a new paradigm of precision medicine by targeting theDNA repair pathway in the context of gene mutations. Its therapeutic effect has made it an important part of the development history of targeted drugs in the past decade, and it also brings hope to more cancer patients in the future.

Reference materials:https://www.drugs.com/mtm/rucaparib.html